Toll-like Receptor Control of MHC Class I Endocytosis

MHC I 类内吞作用的 Toll 样受体控制

基本信息

项目摘要

PROPOSAL SUMMARY Cross-presentation is the process whereby major histocompatibility complex class I (MHC-I) molecules are loaded with peptides derived from an extracellular source of proteins including internalized soluble proteins, microorganisms and dying cells. Cross-presentation is a specialty of dendritic cells (DCs), cell types responsible for priming naïve T cells, but even in DCs, this specialty can come naturally or must be acquired upon activation. Conventional DCs known as cDC1 are potent cross-presenters and can do so constitutively, while inflammatory monocyte-derived DCs found in inflamed tissues and another subset of conventional DCs, cDC2, can also cross- present under conditions of infection and inflammation. Parallel to the well-established heterogeneity of DCs in tissues at steady state and inflammation, DC subsets have different functional states during homeostasis or inflammation. This functional difference is primarily orchestrated by the engagement of innate signaling receptors, such as Toll-like receptors (TLRs), that mediate diverse cellular programs including the transcription of inflammatory genes and mediators, as well as the rapid reorganization of subcellular vesicular traffic through post-translational events such as phosphorylation. It is imperative that we investigate the full spectrum of DC functions under inflammation when innate receptors are engaged, and to not be limited to DC classifications as subsets with rigid inflexible functions. Defining the nature of the inflammatory innate receptors and signals that enable DCs to augment their cross-presentation capacity or to acquire it anew, will inform vaccine design for infectious diseases and cancer where cytotoxic CD8 T cells are absolutely essential for organismal survival. A mechanistic dissection of the regulation of cross-presentation is important for the identification of novel therapeutic targets that can be exploited to harness CD8 T cell immunity and confer long term protection against future infection or cancer resurgence. Antigen internalization, processing, and presentation rely heavily on subcellular vesicular traffic. In vitro tools developed for studying murine conventional DCs have served as the workhorse responsible for seminal discoveries of the mechanisms of cross-presentation and its regulation, which have translated to human DC subsets and have impacted vaccine design and cellular therapies. Such tools have enabled our discovery of endosomal recycling compartment stores of MHC-I critical for cross-presentation and depleted upon infection by immunoevasive viruses, findings that have been replicated in human DCs. We have now discovered a new link between cross-presentation of endocytosed antigen and a particular innate receptor reported to be expressed by cultured DCs, inflammatory DCs and a cDC2 subset. We hypothesize this receptor intersects MHC-I traffic with endocytic antigen to license cross-presentation during infection. Using cultured and ex-vivo DCs isolated from the lymphoid organs of mice, we will define the distinct innate immune signaling components that regulate MHC-I endocytosis. We will determine the features of MHC-I that enable its regulated endocytosis. Our studies will inform urgently needed T cell vaccines against infectious diseases and cancer.
建议总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julie Magarian Blander其他文献

Julie Magarian Blander的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julie Magarian Blander', 18)}}的其他基金

Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation
通过非规范交叉呈递动员不依赖 TAP 的 CD8 T 细胞
  • 批准号:
    10659785
  • 财政年份:
    2023
  • 资助金额:
    $ 25.43万
  • 项目类别:
Modulating XIAP for the Treatment of Inflammatory Bowel Disease
调节 XIAP 治疗炎症性肠病
  • 批准号:
    10727185
  • 财政年份:
    2023
  • 资助金额:
    $ 25.43万
  • 项目类别:
Toll-like receptor control of endocytic antigen cross-presentation
Toll 样受体控制内吞抗原交叉呈递
  • 批准号:
    10735354
  • 财政年份:
    2023
  • 资助金额:
    $ 25.43万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10557150
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
  • 批准号:
    10196978
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
  • 批准号:
    10043494
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of apoptosis in the intestinal epithelium during homeostasis and disease
肠上皮细胞凋亡在稳态和疾病过程中的作用
  • 批准号:
    9926879
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade
TAP 阻断后树突状细胞中的非典型交叉呈递
  • 批准号:
    9404238
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
新型维生素疫苗配方结合了死疫苗的安全性和活疫苗的功效
  • 批准号:
    9357501
  • 财政年份:
    2016
  • 资助金额:
    $ 25.43万
  • 项目类别:
Control of protective immunity by innate pathways sensing bacterial viability
通过感知细菌活力的先天途径控制保护性免疫
  • 批准号:
    8295078
  • 财政年份:
    2012
  • 资助金额:
    $ 25.43万
  • 项目类别:

相似海外基金

Analysis of structure of a lipoticoic acid with adjuvanticity exposed on the surface of lactic acid bacteria
乳酸菌表面具有佐剂作用的硫辛酸的结构分析
  • 批准号:
    17K06935
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding the mechanisms of hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in mucosal adjuvanticity
了解羟丙基-β-环糊精 (HP-β-CD) 粘膜佐剂作用的机制
  • 批准号:
    17K16068
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Alum's adjuvanticity
明矾的佐剂作用
  • 批准号:
    7949067
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of NLRP3-inflammasome in alum's adjuvanticity
NLRP3炎症小体在明矾佐剂中的作用
  • 批准号:
    8012858
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of NLRP3-inflammasome in alum's adjuvanticity
NLRP3炎症小体在明矾佐剂中的作用
  • 批准号:
    8206798
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of NLRP3-inflammasome in alum's adjuvanticity
NLRP3炎症小体在明矾佐剂中的作用
  • 批准号:
    8602799
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Alum's adjuvanticity
明矾的佐剂作用
  • 批准号:
    8085825
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of NLRP3-inflammasome in alum's adjuvanticity
NLRP3炎症小体在明矾佐剂中的作用
  • 批准号:
    8417705
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Role of NLRP3-inflammasome in alum's adjuvanticity
NLRP3炎症小体在明矾佐剂中的作用
  • 批准号:
    7897509
  • 财政年份:
    2010
  • 资助金额:
    $ 25.43万
  • 项目类别:
Mechanisms of peanut (A. hypogaea) glycan adjuvanticity.
花生(A.hypogaea)聚糖佐剂的机制。
  • 批准号:
    7919656
  • 财政年份:
    2009
  • 资助金额:
    $ 25.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了